TB Alliance, Mylan In Deal To Commercialize Pretomanid For TB Treatment

(RTTNews) - Mylan N.V. (MYL), and TB Alliance, a not-for-profit drug maker struck a deal to make the experimental drug pretomanid available for use in two investigational drug regimens to treat tuberculosis.

TB Alliance is currently developing pretomanid in three late-stage clinical trials, which are ongoing. The Nix-TB and ZeNix trials are evaluating the BPaL regimen to treat XDR-TB and the related highly resistant forms of TB. The SimpliciTB trial is evaluating the BPaMZ regimen for treating DS-TB in four months, and MDR-TB in six months.

In relation to BpaL regimen TB Alliance has now granted a license to Mylan to make and sell pretomanid, if approved, for XDR-TB and treatment-intolerant or non-responsive MDR-TB.

In the BPaMZ regimen, TB Alliance has licensed pretomanid to for DS- and MDR-TB.